Wednesday, 6 June 2012

Supplemental Application-Hypercholesterolemia-Phase Iii Trial-Pink Sheet-Fda Panel

Coming In Thursday's 'The Pink Sheet' DAILY - FDA User Fee Bill Moves Through House

House is expected to pass FDA user fee bill - Regeneron and Sanofi plan to begin a Phase III trial of their PCSK9 inhibitor for hypercholesterolemia - FDA panel to review GlaxoSmithKline's supplemental application for use of Tykerb in combination with Herceptin in women who failed on Herceptin alone read more..

No comments:

Post a Comment